What Is a FAST Score? Dementia Staging Explained

The FAST score, short for Functional Assessment Staging Test, is a clinical tool that maps Alzheimer’s disease progression across seven major stages, from no detectable deficits all the way through severe functional decline. Developed by Dr. Barry Reisberg and colleagues, it focuses specifically on what a person can and cannot do in daily life rather than on memory test scores alone. That functional focus makes it especially useful for care planning, and it plays a central role in determining hospice eligibility for people with advanced dementia.

What the FAST Scale Measures

Most people think of dementia staging in terms of cognitive ability: how well someone scores on a memory quiz or whether they can recall a list of words. The FAST takes a different approach. It tracks observable, everyday abilities like managing finances, choosing appropriate clothing, bathing independently, and eventually walking and speaking. The idea is that these functional milestones follow a roughly predictable sequence as Alzheimer’s progresses, and tracking them gives clinicians a practical picture of where someone stands.

The scale was designed to cover the full spectrum of Alzheimer’s disease, from the earliest pre-clinical phase of subjective complaints through mild cognitive impairment and into the most advanced stages of dementia.¹ It is derived from the Global Deterioration Scale (GDS), another Reisberg-designed framework, but adds more granular substages in the later phases of illness. That extra detail in the advanced stages is where the FAST becomes most clinically valuable, because it allows providers to distinguish between levels of severe impairment that other tools treat as a single category.²

The Seven Stages

Each FAST stage corresponds to a general level of function. The early stages are subtle and may not look like dementia at all to an outside observer. The later stages involve profound dependence. Here is how they break down:

Stage 1: No functional decline. The person has no subjective or objective difficulties.
Stage 2: Subjective complaints only. The person notices they are more forgetful but performs normally on testing.
Stage 3: Early deficits become noticeable to coworkers or close contacts. This may correspond to mild cognitive impairment. Job performance in demanding roles may suffer.
Stage 4: Difficulty with complex tasks like managing finances, planning a dinner party, or handling travel arrangements. This is generally where a clinical Alzheimer’s diagnosis becomes possible.
Stage 5: The person needs help choosing appropriate clothing for the weather or occasion but can still handle basic self-care like bathing and toileting.
Stage 6: Broken into five substages (6a through 6e), this phase tracks the progressive loss of abilities like dressing independently, bathing, toileting, and controlling urinary and fecal continence.
Stage 7: The most severe phase, broken into six substages (7a through 7f). Speech gradually diminishes from a vocabulary of about half a dozen words to a single word, then to no intelligible speech at all. The person loses the ability to walk, then to sit up, then to smile. The final substage reflects a loss of the ability to hold the head up independently.

The fine-grained substages in stages 6 and 7 are what set the FAST apart from simpler three- or five-tier systems. A person at stage 7a, who can still speak a few words and walk with assistance, is in a very different care situation than someone at stage 7e, who has lost mobility and most voluntary movement. That distinction matters for everything from staffing needs at a care facility to whether hospice referral is appropriate.

How FAST Compares to Other Dementia Scales

The FAST is not the only way to stage dementia. The Clinical Dementia Rating (CDR) and the Global Deterioration Scale (GDS) are also widely used. These tools overlap in some ways but diverge in others. The CDR, for instance, rates cognitive and functional performance across six domains and yields a single composite score. The GDS provides a broader developmental framework. The FAST correlates moderately with the CDR but classifies severity differently; what the CDR calls early-stage dementia (a score of 2) corresponds to a GDS/FAST stage of 3, which can create confusion when providers use different scales for the same patient.²

One practical advantage the FAST holds over cognitive test-based staging is that it does not require the patient to sit through an exam. By the time someone reaches stage 6 or 7, they often cannot meaningfully participate in a paper-and-pencil cognitive test. The FAST can be completed through caregiver interview alone, which makes it usable across the entire disease course. Still, the tool correlates well with cognitive measures: studies in different populations have found strong negative correlations between FAST stage and scores on standard cognitive tests like the Mini-Mental State Examination, meaning that as functional stage worsens, cognitive scores decline in a corresponding pattern.³

The Retrogenesis Model Behind FAST

The ordering of FAST stages is not arbitrary. It is built on a theory called retrogenesis, which proposes that the abilities lost in Alzheimer’s disease disappear in roughly the reverse order that they were acquired during childhood development. A toddler learns to walk before learning to dress independently, and a person with advancing Alzheimer’s typically loses the ability to dress before losing the ability to walk. Toilet training comes after walking in childhood, and incontinence tends to appear after the loss of dressing ability in dementia.⁴

Research has examined this parallel directly by comparing FAST stages with developmental age equivalents. In preliminary work, investigators found that functional abilities at a given FAST stage corresponded to the abilities expected at a specific age in childhood, supporting the idea that Alzheimer’s reverses the developmental sequence.⁵ This concept has been supported by data from clinical, imaging, and neuropathological sources, and it provides the theoretical backbone for why the FAST stages are ordered the way they are.⁴

Not everyone finds the retrogenesis framework fully satisfying. Brain atrophy in Alzheimer’s does not perfectly mirror the reverse of brain development. MRI-based staging of brain shrinkage shows a progression that is close to, but does not fully overlap with, the Braak staging of tau pathology, the protein tangles that spread through the brain as the disease advances. The earliest brain regions to develop tau tangles are not always the first to show visible atrophy on imaging, which suggests the relationship between tissue-level damage and functional decline is more complicated than a clean reversal of childhood milestones.⁶

Why FAST Stage 7c Matters for Hospice

In the United States, Medicare hospice eligibility for dementia requires a prognosis of six months or less. Because predicting survival in advanced dementia is genuinely difficult, guidelines lean heavily on the FAST score. Specifically, reaching FAST stage 7c, the point at which the person’s speech is limited to a single intelligible word at most, has been used as a benchmark. In one study, patients who had reached stage 7c had a mean survival of about three months, compared with roughly 18 months for patients at earlier stages.⁷

That sounds like a clean threshold, but the evidence on its predictive power is more sobering. When researchers tried to validate FAST stage 7c as a predictor of six-month mortality in a large nursing home population, the statistical discrimination was barely better than a coin flip.⁸ A separate effort to build a more accurate prediction tool, the Advanced Dementia Prognostic Tool (ADEPT), also found that the standard hospice eligibility guidelines based on FAST performed only slightly better than chance.⁹ Even ADEPT itself, which incorporates additional clinical variables like shortness of breath and recent weight loss alongside FAST staging, offered only modest improvement over the guidelines it was designed to replace.¹⁰

The practical takeaway for families is that a FAST stage 7c designation makes someone eligible for hospice, but it does not mean death is imminent in every case. Some people live months or even years beyond that threshold. The scale is more useful as a care-planning framework than as a precise survival clock.

Fast Progressors and Slow Progressors

One of the trickier aspects of Alzheimer’s is that not everyone moves through the FAST stages at the same pace. A large study of 648 patients applied statistical methods to the time people spent at each stage and uncovered two distinct groups: fast progressors and slow progressors. The two groups differed by up to two years in how long they spent at individual FAST stages. Importantly, if a person progressed quickly through one stage, they tended to progress quickly through subsequent stages as well.¹¹

This finding has real implications for families and clinicians. If someone moves through the early-to-middle stages faster than average, the care team should plan ahead aggressively, because the later stages may also arrive sooner. Conversely, slow early progression may offer more time for advance directives, legal planning, and caregiver preparation. The FAST itself does not predict which trajectory a person will follow, but tracking how quickly someone moves from one stage to the next provides a practical signal.

When FAST Stages Do Not Follow the Script

The FAST assumes that functional abilities are lost in a fixed sequence: finances before dressing, dressing before bathing, bathing before continence, and so on. In many Alzheimer’s patients, the progression does follow this ordinal pattern reasonably well. But not always. Some patients skip stages or lose abilities out of order, and when that happens, the FAST becomes harder to score accurately.

In the hospice eligibility study mentioned earlier, patients whose disease did not follow the ordinal FAST sequence had survival times that fell between the high-stage and low-stage groups, with a mean of about nine months, suggesting that non-ordinal progression may represent a middle ground rather than a separate disease pattern.⁷ This is worth knowing because clinicians sometimes struggle to assign a FAST stage to someone whose abilities do not fit the expected hierarchy. The tool works best when progression is orderly, and it loses reliability when it is not.

Other types of dementia, like frontotemporal dementia or Lewy body dementia, may produce functional decline patterns that do not track the FAST sequence at all. The FAST was designed specifically for Alzheimer’s, and applying it to other dementias can produce misleading results. If someone with Lewy body dementia loses motor function early but retains verbal fluency, the FAST stages will not capture their situation well.

Who Is Scoring It Matters

Because the FAST relies on reported observations rather than a standardized cognitive test, the quality of the assessment depends heavily on who is providing the information. Research comparing expert clinicians with family caregivers has found substantially higher agreement on FAST scoring when experts completed the assessment. Caregivers, understandably, sometimes misjudge what constitutes independent function or struggle to distinguish between substages in the later phases.¹²

This does not mean caregiver input is unreliable. Most FAST assessments in clinical practice depend on caregiver reports, and those reports are generally consistent with clinician observations for the major stages. The disagreement tends to show up at the substage level, especially in stages 6 and 7. If you are a caregiver and are asked to help score the FAST, be as specific as possible about what your loved one can and cannot do. Instead of saying “she needs help with everything,” describe exactly which tasks she can still initiate or complete with cueing versus which ones require full physical assistance.

Cross-Cultural Use of the FAST

An important question for any clinical tool is whether it works across different populations. Cognitive tests like the Mini-Mental State Examination are notoriously sensitive to education level and cultural background; someone with limited formal schooling may score poorly on orientation or calculation questions for reasons that have nothing to do with dementia. The FAST, because it measures everyday function rather than school-type knowledge, has shown some resilience to these confounders.

A validation study of a Persian-language version of the FAST in Iran tested its ability to distinguish between healthy older adults, people with mild cognitive impairment, and those with Alzheimer’s disease. The instrument performed well, with sensitivity above 92% and specificity above 93% for distinguishing between diagnostic groups. The researchers concluded the translated FAST was relatively free of the confounding effects of education, culture, and language compared with the MMSE.¹ Similar validation work has been conducted in Korean populations, where the FAST again correlated well with cognitive measures.³

This cross-cultural adaptability is one of the FAST’s quiet strengths. In settings where formal cognitive testing may be biased by literacy or language barriers, a functional assessment that asks “can this person dress herself?” or “does he still recognize close family members?” may give a more accurate picture of where the disease stands.

What Happens to the Body in Late FAST Stages

Most discussions of dementia staging focus on cognition and daily function, but the late FAST stages involve significant physical changes as well. One of the most clinically important is the development of contractures, a permanent tightening of muscles and tendons that locks joints into a fixed position. Research has shown a strong correlation between the severity of functional impairment and the presence of contractures. More than three-quarters of patients who had lost the ability to walk had contractures, while fewer than 11% of those who could still walk were affected. When contractures did develop, they almost always involved multiple limbs, with more than two-thirds of affected patients having all four extremities involved.¹³

Contractures are painful, make repositioning difficult, increase the risk of skin breakdown, and complicate basic care like hygiene and wound management. They are not an inevitable consequence of reaching FAST stage 7, but they become dramatically more likely once walking is lost. Physical therapy, range-of-motion exercises, and positioning programs can reduce the risk, and starting early, while the person is still ambulatory, is far more effective than trying to reverse a contracture after it has formed.

Medications and FAST Staging

Families often wonder whether medications for Alzheimer’s can slow progression through the FAST stages. The evidence is mixed and generally modest. Current cholinesterase inhibitors and memantine may provide small, temporary functional benefits in some patients, but they do not halt or reverse the disease trajectory in a way that would meaningfully shift FAST staging over time.

One interesting finding from a randomized trial looked at whether continuing or stopping antipsychotic medications in dementia patients made any difference to FAST scores. It found no difference whatsoever between the group that continued their antipsychotic and the group switched to placebo.¹⁴ That trial was not designed to test whether antipsychotics could slow dementia, but the result is a useful reminder: many medications given to dementia patients are targeting symptoms like agitation and psychosis, not the underlying disease progression that the FAST measures. Stopping those medications, when done carefully and with medical supervision, does not necessarily accelerate functional decline.

Newer disease-modifying therapies targeting amyloid plaques, like lecanemab and donanemab, have shown statistically significant slowing of cognitive and functional decline in clinical trials of early Alzheimer’s. Whether those effects translate into meaningful delays in FAST stage transitions over years of real-world use remains an open and actively studied question. These drugs are approved for early-stage disease, well before the FAST stages where hospice eligibility becomes relevant.

Delirium and Temporary FAST Stage Shifts

One situation that catches families off guard is when a person with dementia suddenly seems much worse after a hospitalization, an infection, or a medication change. This rapid decline may look like a jump of several FAST stages in a matter of days, but it often reflects delirium superimposed on dementia rather than true disease progression. Delirium is an acute, usually reversible state of confusion caused by a medical trigger, and it is extremely common in hospitalized older adults with underlying dementia.

The critical thing to know is that delirium can make someone appear to be at a much later FAST stage than they actually are. A person who was at FAST stage 5 last week may seem to be at stage 7 during a urinary tract infection. If the infection is treated and the delirium resolves, they may return close to their baseline. Families and clinicians should be cautious about restaging someone during an acute medical event. The FAST is meant to capture the person’s stable, day-to-day functional level, not their worst moment during a crisis.

That said, delirium episodes in people with dementia are not entirely benign even when they resolve. Repeated bouts of delirium have been associated with faster long-term cognitive decline, so while the immediate drop may be reversible, the cumulative impact may nudge someone toward the next FAST stage sooner than they would otherwise have arrived.